Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer
Fouchard, M.; Jantzem, H.; Quere, G.; Descourt, R.; Robinet, G.; Poureau, P-Guillaume.
European Journal of Cancer 115: 107-110
2019
ISSN/ISBN: 0959-8049
PMID: 31132740
DOI: 10.1016/j.ejca.2019.04.022
Accession: 068998400
PDF emailed within 0-6 h: $19.90
Related References
Fouchard, M.; Jantzem, H.; Quere, G.; Descourt, R.; Robinet, G.; Poureau, P.-G. 2019: Three cases of immune cholangitis related to antiprogrammed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer European Journal of Cancer 115: 107-110Sun, X.; Roudi, R.; Dai, T.; Chen, S.; Fan, B.; Li, H.; Zhou, Y.; Zhou, M.; Zhu, B.; Yin, C.; Li, B.; Li, X. 2019: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis Bmc Cancer 19(1): 558
Le Burel, Sébastien.; Champiat, Séphane.; Mateus, C.; Marabelle, Aélien.; Michot, J-Marie.; Robert, C.; Belkhir, R.; Soria, J-Charles.; Laghouati, S.; Voisin, A-Laure.; Fain, O.; Mékinian, Aène.; Coutte, L.; Szwebel, T-Anne.; Dunogeant, L.; Lioger, B.; Luxembourger, Cécile.; Mariette, X.; Lambotte, O. 2017: Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis European Journal of Cancer 82: 34-44
Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J.L.; Rekhtman, N.; Hollmann, T.; Schalper, K.A.; Gainor, J.F.; Shen, R.; Ni, A.; Arbour, K.C.; Merghoub, T.; Wolchok, J.; Snyder, A.; Chaft, J.E.; Kris, M.G.; Rudin, C.M.; Socci, N.D.; Berger, M.F.; Taylor, B.S.; Zehir, A.; Solit, D.B.; Arcila, M.E.; Ladanyi, M.; Riely, G.J.; Schultz, N.; Hellmann, M.D. 2018: Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(7): 633-641
Rivera, N.; Boada, A.; Bielsa, M.Isabel.; Fernández-Figueras, M.Teresa.; Carcereny, E.; Moran, M.Teresa.; Ferrándiz, C. 2017: Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer JAMA Dermatology 153(11): 1162-1165
Chen, J.; Chen, Y.; Feng, F.; Chen, C.; Zeng, H.; Wen, S.; Xu, X.; He, J.; Li, J. 2018: Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer Journal of Thoracic Disease 10(12): 6711-6721
Ilie, M.; Juco, J.; Huang, L.; Hofman, V.; Khambata-Ford, S.; Hofman, P. 2018: Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients Cancer Cytopathology 126(4): 264-274
Santoni, M.; Conti, A.; Buti, S.; Bersanelli, M.; Foghini, L.; Piva, F.; Giulietti, M.; Lusuardi, L.; Battelli, N. 2018: Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis ImmunoTherapy 10(15): 1303-1313
Iafolla, M.A.J.; Juergens, R.A. 2017: Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer Frontiers in Oncology 7: 67
Arbour, K.C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Martínez-Bernal, G.; Ferrara, R.; Lai, W.Victoria.; Hendriks, L.E.L.; Sabari, J.K.; Caramella, C.; Plodkowski, A.J.; Halpenny, D.; Chaft, J.E.; Planchard, D.; Riely, G.J.; Besse, B.; Hellmann, M.D. 2018: Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(28): 2872-2878
Jove, M.; Vilariño, N.; Nadal, E. 2019: Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer Translational Lung Cancer Research 8(Suppl. 4): S364-S368
Yamane, H.; Isozaki, H.; Takeyama, M.; Ochi, N.; Kudo, K.; Honda, Y.; Yamagishi, T.; Kubo, T.; Kiura, K.; Takigawa, N. 2015: Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines American Journal of Cancer Research 5(4): 1553-1557
Shang, H.; Zhang, Z.; Feng, A.; Yang, X.; Zhang, S.; Zhao, Y.; Zhu, Q.; Mao, Y.; Liu, K.; Tian, Y. 2019: The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis Medicine 98(30): E16439
Cortellini, A.; Bersanelli, M.; Santini, D.; Buti, S.; Tiseo, M.; Cannita, K.; Perrone, F.; Giusti, R.; De Tursi, M.; Zoratto, F.; Marconcini, R.; Russano, M.; Zeppola, T.; Anesi, C.; Filetti, M.; Marchetti, P.; Botticelli, A.; Gelibter, A.; De Galitiis, F.; Vitale, M.Giuseppa.; Rastelli, F.; Tudini, M.; Silva, R.Rita.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Migliorino, M.Rita.; Mallardo, D.; Vanella, V.; Mosillo, C.; Bracarda, S.; Rinaldi, S.; Berardi, R.; Natoli, C.; Ficorella, C.; Porzio, G.; Ascierto, P.A. 2020: Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events European Journal of Cancer 128: 17-26
Remon, J.; Chaput, N.; Planchard, D. 2016: Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer Current Opinion in Oncology 28(2): 122-129